ADAMTSL2 and colorectal carcinoma: ADAMTSL2 expression was found to be significantly associated with poor OS (HR: 1.67; 95% CI: 1.18–2.38; p = 0.004), PFS (HR: 1.55; 95% CI: 1.14–2.11; p = 0.005) and DSS (HR: 1.83; 95% CI: 1.16–2.89; p = 0.010) in CRC patients (Fig 3).